We are pleased to welcome the newest member of our Board of Directors, Julie Aunbirk.
Julie has been with NNE for more than 23 years and has, since July 2022, been heading up NNE’s largest area, covering all Engineering disciplines within Process & Facility Design.
Since 2008, Julie has held various line management positions within Process & Utility, Mechanical, Instrumentation, and Validation. Furthermore, Julie was responsible for NNE’s QMS and Project Execution Model from 2018-2019. Before embarking line management, Julie spent 8 years working with pharmaceutical and biotech projects in Project Management, Engineering Management, Concept development, and Commissioning & Qualification.
The Board of Directors is responsible for the overall strategic management of the company and supervises the performance of the company. It consists of six people, including two employee-elected members from Novo Nordisk Pharmatech. Julie Aunbirk joined the board on March 15 as the successor of Søren Thor Jensen and her competencies within project execution and engineering will be needed for new exciting projects at Novo Nordisk Pharmatech.